On May 8, 2026, Spyre Therapeutics, Inc. (NASDAQ: SYRE) director Michael Henderson executed a series of stock transactions totaling roughly $5.95 million. The sale comprised 89,900 shares and was carried out under the auspices of a Rule 10b5-1 trading plan, which was established on February 6, 2026.
The selling activity was segmented into several distinct transaction blocks throughout the trading day:
- A sale of 2,404 shares at a weighted average price of $72.57 per share, with individual prices ranging from $72.03 to $73.00.
- A disposal of 33,513 shares at a weighted average price of $73.72, with prices spanning between $73.15 and $74.14.
- A sale of 24,814 shares at a weighted average price of $74.76, with individual prices falling between $74.15 and $75.14.
- A final block of 19,269 shares sold at a weighted average price of $75.35, with prices ranging from $75.15 to $75.71.
Following these disposals, Mr. Henderson maintains a direct holding of 88,606 shares in Spyre Therapeutics common stock.
Market Context and Recent Capital Activity
The timing of this insider sale coincides with a period of intense price movement for SYRE. The stock has surged by 432% over the last twelve months, positioning it near its 52-week high of $76. Despite this upward trajectory, some valuation metrics indicate that the stock may be overvalued at its current trading levels.
In addition to recent insider activity, Spyre Therapeutics recently finalized a large-scale public offering. This capital raise generated approximately $463.5 million through the sale of 7,475,000 shares of common stock. The pricing for this offering was set at $62.00 per share, a figure that included the full exercise of the underwriters' option to purchase additional shares. This exceeded the initial expectations which had forecasted gross proceeds of approximately $403 million.
Analyst Perspectives and Clinical Pipeline
Wall Street analysts have recently signaled increased optimism regarding the company's outlook. Stifel updated its price target for Spyre Therapeutics, raising it from $92.00 to $107.00 while maintaining a Buy rating. This move was driven by positive data observations related to SPY001 in the treatment of ulcerative colitis. Investors are also looking toward mid-to-late 2026 for anticipated data regarding SPY002 and SPY003.
Furthermore, Raymond James initiated its coverage of the company with a strong buy rating and an initial price target of $80.00, reflecting growing institutional interest in the firm's potential trajectory.